BRPI0720591A2 - Utilização da 10-[(3r)-1-azabiciclo[2.2.2.]oct-3-ilmetil]-10h-fenotiazin a para o preparo de um medicamento que exerce uma inibição seletiva dos receptores muscarínicos m1, m2, m3 - Google Patents
Utilização da 10-[(3r)-1-azabiciclo[2.2.2.]oct-3-ilmetil]-10h-fenotiazin a para o preparo de um medicamento que exerce uma inibição seletiva dos receptores muscarínicos m1, m2, m3 Download PDFInfo
- Publication number
- BRPI0720591A2 BRPI0720591A2 BRPI0720591-0A BRPI0720591A BRPI0720591A2 BR PI0720591 A2 BRPI0720591 A2 BR PI0720591A2 BR PI0720591 A BRPI0720591 A BR PI0720591A BR PI0720591 A2 BRPI0720591 A2 BR PI0720591A2
- Authority
- BR
- Brazil
- Prior art keywords
- oct
- phenothiazine
- azabicyclo
- methyl
- incontinence
- Prior art date
Links
- 230000005764 inhibitory process Effects 0.000 title claims description 16
- 238000002360 preparation method Methods 0.000 title claims description 9
- 229940126601 medicinal product Drugs 0.000 title description 2
- 206010021639 Incontinence Diseases 0.000 claims description 32
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 claims description 27
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 claims description 27
- HOKDBMAJZXIPGC-MRXNPFEDSA-N 10-[[(3r)-1-azabicyclo[2.2.2]octan-3-yl]methyl]phenothiazine Chemical compound C12=CC=CC=C2SC2=CC=CC=C2N1C[C@@H]1C(CC2)CCN2C1 HOKDBMAJZXIPGC-MRXNPFEDSA-N 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 17
- 238000011282 treatment Methods 0.000 claims description 14
- 230000008602 contraction Effects 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- 206010046543 Urinary incontinence Diseases 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 5
- 206010020853 Hypertonic bladder Diseases 0.000 claims description 3
- 206010066218 Stress Urinary Incontinence Diseases 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 208000008967 Enuresis Diseases 0.000 claims description 2
- 208000036071 Rhinorrhea Diseases 0.000 claims description 2
- 206010039101 Rhinorrhoea Diseases 0.000 claims description 2
- 230000002159 abnormal effect Effects 0.000 claims description 2
- 230000004064 dysfunction Effects 0.000 claims description 2
- 208000013403 hyperactivity Diseases 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims description 2
- 230000000926 neurological effect Effects 0.000 claims description 2
- 230000002035 prolonged effect Effects 0.000 claims description 2
- 230000008733 trauma Effects 0.000 claims description 2
- 210000003708 urethra Anatomy 0.000 claims description 2
- 230000002485 urinary effect Effects 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims 5
- 239000002552 dosage form Substances 0.000 claims 2
- 230000007170 pathology Effects 0.000 claims 2
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000000829 suppository Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- HOKDBMAJZXIPGC-UHFFFAOYSA-N Mequitazine Chemical compound C12=CC=CC=C2SC2=CC=CC=C2N1CC1C(CC2)CCN2C1 HOKDBMAJZXIPGC-UHFFFAOYSA-N 0.000 description 43
- 150000001875 compounds Chemical class 0.000 description 22
- 230000000694 effects Effects 0.000 description 21
- 230000001078 anti-cholinergic effect Effects 0.000 description 19
- 102000005962 receptors Human genes 0.000 description 19
- 108020003175 receptors Proteins 0.000 description 19
- 238000012360 testing method Methods 0.000 description 14
- 102000017925 CHRM3 Human genes 0.000 description 13
- 101150060249 CHRM3 gene Proteins 0.000 description 13
- 230000028327 secretion Effects 0.000 description 13
- 238000001727 in vivo Methods 0.000 description 12
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 10
- 229960004373 acetylcholine Drugs 0.000 description 10
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 230000009471 action Effects 0.000 description 8
- 229960005434 oxybutynin Drugs 0.000 description 8
- 102000017926 CHRM2 Human genes 0.000 description 7
- 101150012960 Chrm2 gene Proteins 0.000 description 7
- 206010039424 Salivary hypersecretion Diseases 0.000 description 7
- 230000027455 binding Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 229930003347 Atropine Natural products 0.000 description 5
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 230000001022 anti-muscarinic effect Effects 0.000 description 5
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 5
- 229960000396 atropine Drugs 0.000 description 5
- 206010013781 dry mouth Diseases 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 230000003551 muscarinic effect Effects 0.000 description 5
- VQCFWQCZFAXTOW-UHFFFAOYSA-N 1-methyl-2-octan-3-yl-10H-phenothiazine Chemical compound CCC(CCCCC)C1=C(C=2NC3=CC=CC=C3SC=2C=C1)C VQCFWQCZFAXTOW-UHFFFAOYSA-N 0.000 description 4
- HOKDBMAJZXIPGC-INIZCTEOSA-N 10-[[(3s)-1-azabicyclo[2.2.2]octan-3-yl]methyl]phenothiazine Chemical compound C12=CC=CC=C2SC2=CC=CC=C2N1C[C@H]1C(CC2)CCN2C1 HOKDBMAJZXIPGC-INIZCTEOSA-N 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 208000008630 Sialorrhea Diseases 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 239000000812 cholinergic antagonist Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 229960005042 mequitazine Drugs 0.000 description 4
- 210000004877 mucosa Anatomy 0.000 description 4
- 239000003149 muscarinic antagonist Substances 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 229960004045 tolterodine Drugs 0.000 description 4
- OOGJQPCLVADCPB-HXUWFJFHSA-N tolterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 OOGJQPCLVADCPB-HXUWFJFHSA-N 0.000 description 4
- BDIAUFOIMFAIPU-UHFFFAOYSA-N valepotriate Natural products CC(C)CC(=O)OC1C=C(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 BDIAUFOIMFAIPU-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010010774 Constipation Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000001713 cholinergic effect Effects 0.000 description 3
- 229960002677 darifenacin Drugs 0.000 description 3
- HXGBXQDTNZMWGS-RUZDIDTESA-N darifenacin Chemical compound C=1C=CC=CC=1C([C@H]1CN(CCC=2C=C3CCOC3=CC=2)CC1)(C(=O)N)C1=CC=CC=C1 HXGBXQDTNZMWGS-RUZDIDTESA-N 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000036724 intravesical pressure Effects 0.000 description 3
- 230000004118 muscle contraction Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 208000026451 salivation Diseases 0.000 description 3
- 210000005070 sphincter Anatomy 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 2
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 150000001982 diacylglycerols Chemical class 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 244000144993 groups of animals Species 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 210000002850 nasal mucosa Anatomy 0.000 description 2
- 229960001416 pilocarpine Drugs 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002287 radioligand Substances 0.000 description 2
- 210000003079 salivary gland Anatomy 0.000 description 2
- 230000016160 smooth muscle contraction Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 210000001635 urinary tract Anatomy 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- 206010027654 Allergic conditions Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 208000015924 Lithiasis Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 1
- 208000009722 Overactive Urinary Bladder Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 239000000219 Sympatholytic Substances 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 208000000921 Urge Urinary Incontinence Diseases 0.000 description 1
- MMWCIQZXVOZEGG-HOZKJCLWSA-N [(1S,2R,3S,4S,5R,6S)-2,3,5-trihydroxy-4,6-diphosphonooxycyclohexyl] dihydrogen phosphate Chemical compound O[C@H]1[C@@H](O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](O)[C@H]1OP(O)(O)=O MMWCIQZXVOZEGG-HOZKJCLWSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 description 1
- 210000003626 afferent pathway Anatomy 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- 230000009989 contractile response Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 230000000742 histaminergic effect Effects 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- RPMBYDYUVKEZJA-UHFFFAOYSA-N methoctramine Chemical compound COC1=CC=CC=C1CNCCCCCCNCCCCCCCCNCCCCCCNCC1=CC=CC=C1OC RPMBYDYUVKEZJA-UHFFFAOYSA-N 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 239000000472 muscarinic agonist Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000036640 muscle relaxation Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 208000020629 overactive bladder Diseases 0.000 description 1
- 208000024449 overflow incontinence Diseases 0.000 description 1
- 210000001002 parasympathetic nervous system Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229940127230 sympathomimetic drug Drugs 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 206010046494 urge incontinence Diseases 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229940044953 vaginal ring Drugs 0.000 description 1
- 239000006213 vaginal ring Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0656002 | 2006-12-28 | ||
| FR0656002A FR2910814B1 (fr) | 2006-12-28 | 2006-12-28 | Utilisation du 10-°(r3)-1-azabicyclo°2.2.2!oct-3-ylmethyl!-10h- phenothiazine pour la preparation d'un medicament exercant une inhibition selective des recepteurs muscariniques m1,2,3 |
| PCT/EP2007/064553 WO2008080924A1 (fr) | 2006-12-28 | 2007-12-26 | Utilisation du 10-[(3r)-1-azabicyclo[2.2.2]oct-3-ylméthyl]-10h-phénothiazine pour la préparation d'un médicament exerçant une inhibition sélective des récepteurs muscariniques m1, m2 et m3 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0720591A2 true BRPI0720591A2 (pt) | 2014-02-25 |
Family
ID=37951872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0720591-0A BRPI0720591A2 (pt) | 2006-12-28 | 2007-12-26 | Utilização da 10-[(3r)-1-azabiciclo[2.2.2.]oct-3-ilmetil]-10h-fenotiazin a para o preparo de um medicamento que exerce uma inibição seletiva dos receptores muscarínicos m1, m2, m3 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8143245B2 (enExample) |
| EP (1) | EP2124956A1 (enExample) |
| JP (1) | JP5564263B2 (enExample) |
| KR (1) | KR101465277B1 (enExample) |
| CN (1) | CN101573120B (enExample) |
| AR (1) | AR064714A1 (enExample) |
| AU (1) | AU2007341274B2 (enExample) |
| BR (1) | BRPI0720591A2 (enExample) |
| CA (1) | CA2674162A1 (enExample) |
| FR (2) | FR2910814B1 (enExample) |
| IL (1) | IL199557A (enExample) |
| MA (1) | MA31026B1 (enExample) |
| MX (1) | MX2009006950A (enExample) |
| NO (1) | NO20092654L (enExample) |
| NZ (1) | NZ577915A (enExample) |
| RU (1) | RU2449794C2 (enExample) |
| TN (1) | TN2009000257A1 (enExample) |
| TW (1) | TWI423806B (enExample) |
| UA (1) | UA98131C2 (enExample) |
| WO (1) | WO2008080924A1 (enExample) |
| ZA (1) | ZA200904304B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015133989A (ja) * | 2015-04-28 | 2015-07-27 | 重泉 達志 | 健康食品 |
| KR101969263B1 (ko) | 2018-07-16 | 2019-04-15 | 이상호 | 산소 챔버용 산소 공급 장치 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1173445B (it) * | 1984-03-16 | 1987-06-24 | Guidotti & C Spa Labor | Agenti ad attivita' antibroncospastica e composizioni farmaceutiche che li contengono |
| IT1251161B (it) * | 1991-08-07 | 1995-05-04 | Derivati ammonio quaternari di (-) e (+)-3-(10 h-fenotiazin-10-ilmetil)-l-azabiciclo (2.2.2.)ottano e composizioni farmaceutiche che li contengono | |
| AU6686700A (en) | 1999-08-23 | 2001-03-19 | H. Lundbeck A/S | Treatment of urinary incontinence |
| AU2002366800B2 (en) * | 2001-12-20 | 2006-08-03 | Femmepharma Holding Company, Inc. | Vaginal delivery of drugs |
-
2006
- 2006-12-28 FR FR0656002A patent/FR2910814B1/fr not_active Expired - Fee Related
-
2007
- 2007-12-13 TW TW096147644A patent/TWI423806B/zh not_active IP Right Cessation
- 2007-12-26 NZ NZ577915A patent/NZ577915A/en not_active IP Right Cessation
- 2007-12-26 US US12/521,067 patent/US8143245B2/en not_active Expired - Fee Related
- 2007-12-26 RU RU2009128326/15A patent/RU2449794C2/ru not_active IP Right Cessation
- 2007-12-26 JP JP2009543465A patent/JP5564263B2/ja not_active Expired - Fee Related
- 2007-12-26 KR KR1020097013047A patent/KR101465277B1/ko not_active Expired - Fee Related
- 2007-12-26 WO PCT/EP2007/064553 patent/WO2008080924A1/fr not_active Ceased
- 2007-12-26 BR BRPI0720591-0A patent/BRPI0720591A2/pt not_active IP Right Cessation
- 2007-12-26 MX MX2009006950A patent/MX2009006950A/es active IP Right Grant
- 2007-12-26 AU AU2007341274A patent/AU2007341274B2/en not_active Ceased
- 2007-12-26 CN CN2007800467680A patent/CN101573120B/zh not_active Expired - Fee Related
- 2007-12-26 EP EP07858150A patent/EP2124956A1/fr not_active Withdrawn
- 2007-12-26 CA CA002674162A patent/CA2674162A1/fr not_active Abandoned
- 2007-12-26 UA UAA200907928A patent/UA98131C2/ru unknown
- 2007-12-28 AR ARP070105989A patent/AR064714A1/es unknown
-
2009
- 2009-01-01 ZA ZA200904304A patent/ZA200904304B/xx unknown
- 2009-06-23 TN TNP2009000257A patent/TN2009000257A1/fr unknown
- 2009-06-25 IL IL199557A patent/IL199557A/en not_active IP Right Cessation
- 2009-06-26 MA MA32046A patent/MA31026B1/fr unknown
- 2009-07-13 NO NO20092654A patent/NO20092654L/no not_active Application Discontinuation
-
2011
- 2011-03-17 FR FR1152199A patent/FR2953721A1/fr active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US8143245B2 (en) | 2012-03-27 |
| JP2010514730A (ja) | 2010-05-06 |
| KR101465277B1 (ko) | 2014-11-27 |
| MX2009006950A (es) | 2009-07-14 |
| AR064714A1 (es) | 2009-04-22 |
| AU2007341274A1 (en) | 2008-07-10 |
| RU2009128326A (ru) | 2011-02-10 |
| JP5564263B2 (ja) | 2014-07-30 |
| RU2449794C2 (ru) | 2012-05-10 |
| FR2953721A1 (fr) | 2011-06-17 |
| AU2007341274B2 (en) | 2012-09-20 |
| HK1133207A1 (en) | 2010-03-19 |
| NZ577915A (en) | 2011-12-22 |
| CN101573120A (zh) | 2009-11-04 |
| TWI423806B (zh) | 2014-01-21 |
| UA98131C2 (ru) | 2012-04-25 |
| KR20090103887A (ko) | 2009-10-01 |
| TN2009000257A1 (fr) | 2010-10-18 |
| WO2008080924A1 (fr) | 2008-07-10 |
| NO20092654L (no) | 2009-09-28 |
| EP2124956A1 (fr) | 2009-12-02 |
| FR2910814B1 (fr) | 2011-06-17 |
| CN101573120B (zh) | 2011-11-23 |
| TW200833331A (en) | 2008-08-16 |
| FR2910814A1 (fr) | 2008-07-04 |
| ZA200904304B (en) | 2010-06-30 |
| CA2674162A1 (fr) | 2008-07-10 |
| US20100063276A1 (en) | 2010-03-11 |
| MA31026B1 (fr) | 2009-12-01 |
| IL199557A (en) | 2014-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kovac | Prevention and treatment of postoperative nausea and vomiting | |
| US20050085463A1 (en) | Use of N-desmethylclozapine to treat human neuropsychiatric disease | |
| US20050250767A1 (en) | Use of N-desmethylclozapine to treat human neuropsychiatric disease | |
| US20090018119A1 (en) | Use of n-desmethylclozapine to treat human neuropsychiatric disease | |
| JP2010168404A (ja) | 睡眠時無呼吸の薬理学的処置 | |
| WO2006023703A2 (en) | Method for treating sleep related breathing disorders | |
| JP3222524B2 (ja) | 下部尿路障害の処置剤 | |
| US20220125803A1 (en) | Methods for the treatment of perimenopause and menopause | |
| KR20000075572A (ko) | 뇨 실금, 동요병 및 어지러움을 치료하는 약물을 제조하는데있어서 데스카르보에톡시로라타딘을 이용하는 방법 | |
| ES2238781T3 (es) | Utilizacion de la mirtazapina para la obtencion de un medicamento para el tratamiento de las apneas del sueño. | |
| EP1843765A2 (en) | The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome | |
| BRPI0713733A2 (pt) | métodos para diminuir os sintomas de depressão e para tratar uma ou mais condições psicológicas, composição farmacêutica e kit | |
| AU2007341274B2 (en) | Use of 10-[(3R)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-10H-phenothiazine for the preparation of a drug having a selective inhibition of muscarinic M1, M2 and M3 receptors | |
| JP2008509147A (ja) | ヒト神経精神病を治療するためのｎ−デスメチルクロザピンの使用 | |
| Hibbs et al. | Agents acting at the neuromuscular junction and autonomic ganglia | |
| Srinivasan et al. | Melatonin agonists for treatment of sleep and depressive disorders | |
| CN105377255A (zh) | 苯氧基丙胺化合物治疗抑郁症的使用方法 | |
| ES2362926T3 (es) | Nueva combinación de fármacos como un antidepresivo. | |
| PT1965800E (pt) | Métodos de tratamento das incontinências | |
| HK1133207B (en) | Use of 10-[(3r)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-10h-phenothiazine for the preparation of a drug having a selective inhibition of muscarinic m1, m2 and m3 receptors | |
| Prasad | Chemistry and Synthesis of Medicinal Agents:(Expanding Knowledge of Drug Chemistry) | |
| Meti | Ramosetron vs Palonosetron in Preventing Postoperative Nausea and Vomiting in Laparoscopic Surgeries-A Clinical Comparision | |
| Wein et al. | Pharmacologic management of urinary incontinence | |
| Wonderlin | Muscarinic Blocking Drugs | |
| JP2007519698A (ja) | 中枢神経系の疾患および障害の治療および予防用の医薬処方を製造するためのベンゾナフトアズレン類の使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |